We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
Cap. Flow
-$105M
Cap. Flow %
-4.06%
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$42.8M
2
ABBV icon
AbbVie
ABBV
+$22.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.8M
4
CELG
Celgene Corp
CELG
+$14.3M
5
NVO
Novo Nordisk
NVO
+$10.1M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$25.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$24.3M
3
AGN
Allergan plc
AGN
+$23.5M
4
GILD icon
Gilead Sciences
GILD
+$21.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.75%
2 Real Estate 2.87%
3 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMR icon
151
The RMR Group
RMR
$333M
$441K 0.02%
7,441
– –
XNCR icon
152
Xencor
XNCR
$1.59B
$438K 0.02%
20,000
– –
CAH icon
153
Cardinal Health
CAH
$53.2B
$386K 0.01%
6,300
-70,300
-92% -$4.35M
ADYX
154
DELISTED
Adynxx Inc
ADYX
$302K 0.01%
27,500
– –
CLDX icon
155
Celldex Therapeutics
CLDX
$3.02B
$300K 0.01%
7,053
– –
QHC
156
DELISTED
Quorum Health Corporation
QHC
$148K 0.01%
23,725
– –
LRMR icon
157
Larimar Therapeutics
LRMR
$398M
$61K ﹤0.01%
1,109
– –
AXDX
158
DELISTED
Accelerate Diagnostics
AXDX
– –
-15,000
Closed -$3.37M
KPTI icon
159
Karyopharm Therapeutics
KPTI
$159M
$0 ﹤0.01%
1
-50,444
-100% -$8.1M
UHS icon
160
Universal Health Services
UHS
$9.88B
– –
-48,076
Closed -$5.33M
EIGR
161
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,034
Closed -$341K
ICPT
162
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-123,200
Closed -$7.15M
GNMK
163
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-294,749
Closed -$2.84M
MNTA
164
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-152,900
Closed -$2.83M
JUNO
165
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-56,900
Closed -$2.55M
ENTL
166
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
– –
-341,471
Closed -$6.3M
3 4 5 6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.

  • Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
  • Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
  • Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
  • Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
  • Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
  • Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.